APOLLO HOSPITALS ENTERPRISE LIMITED

CIN: L85110TN1979PLC008035



12th November 2021

The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code – 508869 ISIN INE437A01024

The Secretary, National Stock Exchange, Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra – Kurla Complex Bandra (E) Mumbai – 400 051. Scrip Code– APOLLOHOSP ISIN INE437A01024 The Manager The National Stock Exchange, Wholesale Debt Market Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra – Kurla Complex Bandra (E) Mumbai – 400 051. **ISIN INE437A07120**

Dear Sir,

Sub: Limited Review Report on unaudited financial results for the quarter and half year ended September 30, 2021 with UDIN.

In continuation of the Company's unaudited financial results (both standalone and consolidated) for the quarter and half year ended September 30, 2021 ("the Results") filed with the stock exchanges today, please find attached the auditor's Limited Review Report on the Results (both standalone and consolidated), with Unique Document Identification Number ("UDIN").

Kindly take the above in your records.

Thanking you,

Yours faithfully, For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN Sr. VICE PRESIDENT – FINANCE AND COMPANY SECRETARY

IS/ISO 9001:2000

Regd. Office : 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. General Office : "Ali Towers", III Floor, #55, Greams Road, Chennai - 600 006. Tel : 044 - 28290956 / 3896 / 6681 Telefax : 044 - 2829 0956 Email : investor.relations@apollohospitals.com Website: www.apollohospitals.com

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

- We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Company"), for the three and six months ended September 30, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants (Firm's Registration No. 117366W/W-100018)

> VIKAS Digitally signed by VIKAS BAGARIA BAGARIA Date: 2021.11.12 20:13:01 +05'30'

Vikas Bagaria Partner (Membership No. 060408) UDIN: 21060408AAAADG6731

Place: Bengaluru Date: November 12, 2021

Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru – 560 001 Karnataka, India

Tel: +91 80 6188 6000 Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income(net) of its associates and joint ventures for the three months ended September 30,2021 and its shares of net loss after tax and total comprehensive expense (net) of its associates and joint ventures for the six months ended September 30, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited	Parent
Apollo Home Healthcare Limited	Subsidiary
AB Medical Centers Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Private Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Surya Fertility Center Private Limited	Stepdown Subsidiary of AHLL
Apollo Bangalore Cradle Limited	Stepdown Subsidiary of AHLL
Kshema Healthcare Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapein Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo-Amrish Oncology Services Private Limited	Associate of AHIL
Apollo CVHF Limited	Subsidiary of AHIL
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited	Subsidiary
Medics International Lifesciences Limited	Subsidiary
Apollo Medical Private Limited (AMPL)	Associate
Apollo Pharmacy Limited	Subsidiary of AMPL
Apollo Multi Specialty Hospitals Limited (formerly Apollo Gleneagles Hospitals Limited)	Subsidiary (refer Note 3 of the consolidated financial results)
Apollo HealthCo Limited	Subsidiary
Apollo Gleneagles PET-CT Private Limited	Joint venture
ApoKos Rehab Private limited	Joint venture
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate

4. The Statement includes the results of the following entities:

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We draw attention to Note 8 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka, as reported by the other auditors of the said subsidiary company. Our conclusion on the Statement is not modified in respect of this matter.
- 7. We did not review the financial results of 21 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs. 184.239 lakhs as at September 30,2021, total revenues of Rs.37,414 lakhs and Rs. 72,999 lakhs for the three and six months ended September 30,2021, total net profit after tax of Rs. 4,022 lakhs and Rs. 7,214 lakhs for the three and six months ended September 30,2021 respectively and total comprehensive income of Rs. 3,746 lakhs and Rs. 7,124 lakhs for the three and six months ended September 30,2021 respectively and net cash flows of Rs.1,983 lakhs for the six months ended September 30, 2021, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of net profit after tax of Rs. 215 lakhs and Group's share of net loss of Rs. 267 lakhs for the three and six months ended September 30. 2021 respectively and Total comprehensive income of Rs. 34 lakhs and Total comprehensive expense of Rs.255 lakhs for the three and six months ended September 30,2021 respectively, as considered in the Statement, in respect of 1 joint ventures and 3 associates, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial results of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs. 1,801 lakhs as at September 30,2021 and, total revenue of Rs. Nil lakhs and Rs. Nil lakhs for the three and six months ended September 30, 2021 respectively, total profit after tax of Rs.249 lakhs and Rs. 258 lakhs for the three and six months ended September 30, 2021 respectively and Rs. 258 lakhs for the three and six months ended September 30, 2021 respectively and Rs. 258 lakhs for the three and six months ended September 30, 2021 respectively and net cash flows (net) of Rs. Nil for the six months ended September 30, 2021, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 13 lakhs. and Rs. 104 lakhs for the three and six months ended September 30, 2021 respectively, as considered in the Statement, in respect of 1 associate and 1 joint venture, based on their interim financial results which

have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim results certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants (Firm's Registration No. 117366W/W-100018)

VIKAS Digitally signed by VIKAS BAGARIA BAGARIA Date: 2021.11.12 20:12:21 +05'30'

Vikas Bagaria Partner (Membership No. 060408) UDIN: 21060408AAAADH4064

Place: Bengaluru Date: November 12, 2021